Stryker Corporation $SYK Stock Position Raised by Deutsche Bank AG

Deutsche Bank AG increased its stake in Stryker Corporation (NYSE:SYK) by 22.2% during the second quarter, HoldingsChannel.com reports. The fund owned 1,438,910 shares of the medical technology company’s stock after buying an additional 261,687 shares during the period. Deutsche Bank AG’s holdings in Stryker were worth $453,026,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. Sankala Group LLC acquired a new stake in Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker during the fourth quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker during the fourth quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 2.2%

SYK opened at $331.75 on Tuesday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The business has a 50-day moving average of $325.21 and a 200-day moving average of $333.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $127.25 billion, a PE ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the business posted $3.13 EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on SYK shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. BMO Capital Markets initiated coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. Finally, Citizens Jmp cut their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.